Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Goldman Sachs Maintains Buy on Day One Biopharmaceutical, Lowers Price Target to $43

Author: Benzinga Newsdesk | February 10, 2025 12:01pm

Goldman Sachs analyst Andrea Tan maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and lowers the price target from $48 to $43.

Posted In: DAWN